BC Partners
BC Partners operates Private Equity and Private Credit strategies. Its Private Equity strategy focuses on upper-mid-market companies with defensible characteristics, market leadership, high-quality management, and multiple value-creation levers.
What stands out about BC Partners
BC Partners publicly describes its Private Equity strategy as upper-mid-market focused, with activity across Europe and North America and sector coverage spanning TMT, Services & Industrials, Healthcare, and Food. The firm states that each investment is supported by an actively managed value-creation plan.[1][2][6][8]
What does BC Partners invest in?
BC Partners is an alternative investment manager founded in 1986 and focused on Private Equity and Private Credit. The firm states that it has approximately €35 billion in assets under management across the two strategies.
Its Private Equity strategy partners with market-leading companies in the upper mid-market that have defensible characteristics and multiple levers for growth and value creation.[1][2]
BC Partners states that each Private Equity investment is supported by an actively managed value-creation plan. The potential levers it identifies include organic growth, M&A, strategic repositioning, international expansion, operational improvement, new products, fragmented-market consolidation, and efficiency initiatives.
The firm describes its Private Equity strategy as focused on market-leading upper-mid-market companies with defensible characteristics and multiple growth and value-creation levers.[2]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with BC Partners?
An owner evaluating BC Partners can compare the company’s characteristics with the firm’s stated focus on upper-mid-market, market-leading businesses with defensible characteristics, high-quality management, and multiple value-creation levers.
Discussion points include the relevant sector team, the applicable Private Equity or Private Credit strategy, the proposed equity and transaction size, ownership expectations, governance, management incentives, leverage, reporting, and the value-creation plan. The cited Private Equity strategy page does not state a universal transaction-size range or an explicit ownership-duration policy, so those points require direct confirmation.[1][2][3]
What is the current equity investment range and enterprise-value range for the relevant BC Partners fund
Which investment team and sector partner would lead the opportunity
How would BC Partners apply its value-creation plan to the company
What companies does BC Partners target?
BC Partners states that it values market leadership, mission-critical products or services, high-quality management teams, predictable or contracted revenues, margin resilience, low capital intensity, proprietary content or intellectual property, and cash yield.
The firm describes the strategy as upper-mid-market focused with large-cap capabilities.[2]
BC Partners’ Private Equity activities focus on four sectors across Europe and North America: TMT, Services & Industrials, Healthcare, and Food.[3]
BC Partners states that its Private Equity activities cover Europe and North America. It identifies investment activity across the UK and Ireland, France and BeNeLux, Italy and Spain, DACH, North America, and other markets.
The firm states that it has partnered with 130 companies in approximately 19 countries.[2][3]
The sources cited for this profile do not establish a formal platform-versus-add-on framework.
BC Partners’ official portfolio page identifies selected investments including Acuris, Aenova, Altice USA, Antelliq, Biogaran, CeramTec, Cigierre, Davies, DentalPro, and EAB.
Its official all-investments page also categorizes named investments by sector and region, including Accudyne, Fedrigoni, Forno d’Asolo, GFL, GardaWorld, Madison Logic, NAVEX, and Presidio.[4][5]
On July 28, 2026, BC Partners announced an agreement to acquire a co-control stake in InfoRLife SA from its founder and the founding families of ACS Dobfar, in partnership with ACS Dobfar.
On January 30, 2026, BC Partners and Bpifrance announced completion of the acquisition of Biogaran from Servier, with Bpifrance as a significant minority shareholder and board member.
On February 27, 2025, BC Partners announced an agreement to acquire a majority stake in PetLab Co., while its co-founders retained a significant investment.[6][7][8]
What is not clear from BC Partners's public investment criteria?
The cited InfoRLife transaction release states that the terms of that transaction were not disclosed. The cited PetLab Co. transaction release likewise states that the terms were not disclosed.
The cited Private Equity strategy page does not state a universal transaction-size range or an explicit ownership-duration policy.[2][6][8]
Questions to ask when evaluating BC Partners as a buyer or investment partner
What is the current equity investment range and enterprise-value range for the relevant BC Partners fund?
Which investment team and sector partner would lead the opportunity?
How would BC Partners apply its value-creation plan to the company?
What percentage of equity would BC Partners seek, and what rollover would be expected from existing owners?
What is the expected ownership horizon and exit-planning approach for this strategy?
What are the proposed governance, management-incentive, leverage, reporting, and ESG requirements?
Sources & research notes
- Official website / firm overview
- Investment strategy
- Industry / market focus
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.